CoChat

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial

Open access
Laffin, Luke J., Rodman, David, Luther, James M., Vaidya, Anand, Weir, Matthew R., Rajicic, Natasa, Slingsby, B. T., Nissen, Steven E., Target-HTN Investigators, Beasley, Richard, Budoff, Matthew, Carr, George, Carroll, Michael, Cevallos Yepez, Jose, Chhabra, Anil, Cole, Frank, Dunn, Leonard, Eaves, William, Ebuh, Valentine, Estevez, Roger, Gould, Glenn, Hong, Matthew, Iteld, Bruce, Jain, Mahendra, Kemp, Charles, Kennelly, Christina, Kleiner, Mark, Kutner, Mark, Laffin, Luke, Lambert, Joseph, Ledesma, Gilbert, Lee, Keung, Lentz, John, Lupovitch, Steven, Luther, James, Lynn, Lon, Marquez, Obadias, Mazhar, Mobeen, Morin, David, Neutel, Joel, Oppong, Yaa, Osorio, Merlin, Patron, Andres, Pharr, Walter, Ponce de Leon, Mercedes, Rodriguez-Ables, Lilia, Rosen, Jeffrey, Sachmechi, Issac, Surowitz, Ronald, Wadsworth, Larkin, Wayne, Jeffrey, Zafar, Zahid · 2023 · JAMA
Cited by 214

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Importance: Excess aldosterone production contributes to hypertension in both classical hyperaldosteronism and obesity-associated hypertension. Therapies that reduce aldosterone synthesis may lower blood pressure. Objective: To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials. Design, Setting, and Participants: Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications. An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h. Interventions: Participants were randomized to placebo or 1 of 5 dosages of lorundrostat in the initial cohort (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily). In the second cohort, participants were randomized in a 1:6 ratio to placebo or lorundrostat, 100 mg once daily. Main Outcomes and Measures: The primary end point was change in automated office systolic blood pressure from baseline to study week 8. Results: Between July 2021 and June 2022, 200 participants were randomized, with final follow-up in September 2022. Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were −10.1 and −13.8 mm Hg, respectively. The least-squares mean difference between placebo and treatment in systolic blood pressure was −9.6 mm Hg (90% CI, −15.8 to −3.4 mm Hg; P = .01) for the 50-mg once-daily dose and −7.8 mm Hg (90% CI, −14.1 to −1.5 mm Hg; P = .04) for 100 mg daily. Among participants without suppressed PRA, 100 mg once daily of lorundrostat decreased systolic blood pressure by 11.4 mm Hg (SD, 2.5 mm Hg), which was similar to blood pressure reduction among participants with suppressed PRA receiving the same dose. Six participants had increases in serum potassium above 6.0 mmol/L that corrected with dose reduction or drug discontinuation. No instances of cortisol insufficiency occurred. Conclusions and Relevance: Among individuals with uncontrolled hypertension, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies. Trial Registration: ClinicalTrials.gov Identifier: NCT05001945

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2023.16029

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 214

Metadata

Authors
Laffin, L. J., Rodman, D., Luther, J. M., Vaidya, A., Weir, M. R., Rajicic, N., Slingsby, B. T., Nissen, S. E., Target-HTN Investigators, Beasley, R., Budoff, M., Carr, G., Carroll, M., Cevallos Yepez, J., Chhabra, A., Cole, F., Dunn, L., Eaves, W., Ebuh, V., Estevez, R., Gould, G., Hong, M., Iteld, B., Jain, M., Kemp, C., Kennelly, C., Kleiner, M., Kutner, M., Laffin, L., Lambert, J., Ledesma, G., Lee, K., Lentz, J., Lupovitch, S., Luther, J., Lynn, L., Marquez, O., Mazhar, M., Morin, D., Neutel, J., Oppong, Y., Osorio, M., Patron, A., Pharr, W., Ponce de Leon, M., Rodriguez-Ables, L., Rosen, J., Sachmechi, I., Surowitz, R., Wadsworth, L., Wayne, J., & Zafar, Z.
Venue
JAMA
Published
2023-09-26
Volume
330
Issue
12
Pages
1140
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4386584720
Cited by
214
References
5
FWCI
35.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2023.16029
The paper
Laffin, L. J., Rodman, D., Luther, J. M., Vaidya, A., Weir, M. R., Rajicic, N., Slingsby, B. T., Nissen, S. E., Target-HTN Investigators, Beasley, R., Budoff, M., Carr, G., Carroll, M., Cevallos Yepez, J., Chhabra, A., Cole, F., Dunn, L., Eaves, W., Ebuh, V., . . . Zafar, Z. (2023). Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.16029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.